Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PELOPS
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
- NCT02764541 ↗
- Active, not recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on PELOPS (palbociclib in early invasive lobular or ductal breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PELOPS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Letrozole; Tamoxifen; Palbociclib; Endocrine Therapy
- Arms
- Arm A Tamoxifen followed by Endocrine Therapy · Experimental
- Arm B Letrozole Followed By Endocrine Therapy · Experimental
- Tamoxifen Followed By Endocrine Therapy and Palbociclib · Experimental
- Letrozole Followed By Endocrine Therapy and Palbociclib · Experimental
- Enrollment
- 195
- Primary outcomes
- Difference in Anti-proliferative Activity of Patients Given Letrozole Versus Tamoxifen During the Window Phase
- Pathologic Complete Response (pCR) of Patients Given Endocrine Therapy Plus Palbociclib and of Endocrine Therapy Alone During the Treatment Phase
- Sponsor
- Dana-Farber Cancer Institute with Pfizer
- Start
- May 24, 2016
- Primary completion
- Feb 2022
- Results posted
- Yes
- Registry record
- NCT02764541 · updated Jun 23, 2026
Publications
linked from the registry- Grinshpun A, Dustin D, Cai M, Hughes M, DiLullo M, Moore M, Yardley D, Mayer IA, Symmans WF, Mayer EL, Winer EP, Lin NU, Tolaney SM, Metzger O, Jeselsohn R. Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer. ESMO Open. 2026 Mar;11(3):106067. doi: 10.1016/j.esmoop.2026.106067. Epub 2026 Feb 10. PubMed 41672025
- Weiss A, Jin Q, Tayob N, Wrabel E, DeMeo M, Carter J, Constantine M, Faggen M, Block C, Fenton MA, Lo KMS, Openshaw T, Yardley D, Kennedy L, Bedrosian I, Mittendorf EA, Jeselsohn R, Metzger Filho O, King TA. Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial. Ann Surg Oncol. 2026 Mar;33(3):2275-2283. doi: 10.1245/s10434-025-18697-5. Epub 2025 Nov 23. PubMed 41276768
- Weiss A, Revette A, Nava-Coulter B, Mittendorf EA, Filho OM, King TA. Surgeon Perspectives on Axillary Management Following Neoadjuvant Endocrine Therapy: Results from a Qualitative Substudy of the PELOPS Trial. Ann Surg Oncol. 2026 Mar;33(3):2267-2274. doi: 10.1245/s10434-025-18695-7. Epub 2025 Nov 21. PubMed 41272386
- Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garcia-Pedrero J, Canadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 Oct 2;83(19):3284-3304. doi: 10.1158/0008-5472.CAN-23-1711. PubMed 37450351